Lv1
28 积分 2025-02-06 加入
Clinically Oriented CBCT Periapical Lesion Evaluation via 3D CNN Algorithm
24天前
已完结
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
25天前
已完结
Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial
25天前
已完结
Diabetic Kidney Disease
30天前
已完结
The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments
1个月前
已完结
American Association of Oral and Maxillofacial Surgeons’ Position Paper on Medication-Related Osteonecrosis of the Jaws—2022 Update
1个月前
已完结
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
1个月前
已完结
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
1个月前
已完结
#3015 EFFECT OF DAPAGLIFLOZIN ON ALBUMINURIA IN PATIENTS WITH TYPE 2 DIABETES AND CKD
2个月前
已完结
SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review
2个月前
已完结
皖公网安备34019202002308
